Eyepoint Pharmaceuticals (EYPT) Issues Earnings Results

Eyepoint Pharmaceuticals (NASDAQ:EYPT) issued its quarterly earnings data on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02, Morningstar.com reports. The business had revenue of $2.44 million for the quarter, compared to the consensus estimate of $0.66 million. Eyepoint Pharmaceuticals had a negative net margin of 2,622.93% and a negative return on equity of 193.49%.

Shares of NASDAQ:EYPT traded up $0.01 during midday trading on Friday, reaching $2.47. The company’s stock had a trading volume of 72,830 shares, compared to its average volume of 326,682. The company has a market capitalization of $233.34 million, a PE ratio of -4.26 and a beta of 2.01. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.57 and a quick ratio of 2.57. Eyepoint Pharmaceuticals has a 12-month low of $1.05 and a 12-month high of $3.94.

Large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Eyepoint Pharmaceuticals in the 4th quarter worth about $31,000. Private Advisor Group LLC acquired a new stake in shares of Eyepoint Pharmaceuticals in the 3rd quarter valued at approximately $134,000. B. Riley Wealth Management Inc. acquired a new stake in shares of Eyepoint Pharmaceuticals in the 3rd quarter valued at approximately $164,000. Bank of New York Mellon Corp lifted its holdings in shares of Eyepoint Pharmaceuticals by 78.5% in the 4th quarter. Bank of New York Mellon Corp now owns 51,501 shares of the company’s stock valued at $97,000 after buying an additional 22,645 shares during the period. Finally, California Public Employees Retirement System acquired a new stake in shares of Eyepoint Pharmaceuticals in the 2nd quarter valued at approximately $135,000. 57.99% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have issued reports on EYPT shares. ValuEngine downgraded shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. HC Wainwright set a $5.00 target price on shares of Eyepoint Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, January 4th. Finally, Zacks Investment Research raised shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Thursday, February 7th.

WARNING: This article was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://sportsperspectives.com/2019/03/15/eyepoint-pharmaceuticals-eypt-issues-earnings-results.html.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.

Featured Article: Back-End Load

Earnings History for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.